Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2004

View Archived Issues

U.K. approval for Striant SR

CyDex allows Gilead use of Captisol technology for early clinical study

Biosite enters discovery collaboration with DMI BioSciences

Bionomics anticancer IP advances into drug discovery

Progression of gene vector manufacturing for GeneMax TAP cancer vaccine

SYN X reacquires rights to Alzheimer's diagnostic technology

Solvay reports favorable development of R&D portfolio

Antibacterial efficacy of oritavancin

Antibacterial effects of daptomycin in patients with cSSSI

Vertex highlights 2003 developments

Procter & Gamble present data on novel MMP inhibitor, PG-530742, at ACC

Tyrosine kinase receptor inhibitor prevents restenosis after coronary stenting in porcine model

New anti-TACI receptor antibodies and their use reported by Genentech

Pfizer describes inhibitors of CDKs and tyrosine kinases and their therapeutic use

Novel cathepsin K inhibitors prepared and tested by Korean researchers

Nippon Shinyaku scientists discover Bcr-Abl kinase inhibitors for use in leukemia therapy

Novel LXR agonists identified by Merck researchers

New hypoglycemic and hypolipidemic agents claimed by Bayer

NitroMed presents novel COX-2 inhibitors in a recent patent

Kyowa Hakko scientists develop PDE10A inhibitors for Parkinson's disease and other uses

Schering plans introduction of new drugs in coming years

Orphan drug status for AT-1001 for Fabry's disease

BioTie Therapies and Aventis sign agreement for new heparin-like drug

Positive results from Xibrom phase III studies

CE Mark for Durolane for osteoarthritis of the hip joint

Phase II study for MT-201 in breast cancer

New phase I/IIa study to evaluate Telcyta combination therapy for NSCLC

FDA approval for Sensipar

Patient enrollment completed for a phase IV trial with Spiriva

Antiarrhythmic effects of ranolazine in isolated myocytes

Antiinflammatory effects induced by AGI-1067 in atherosclerosis

New data on the antihypertensive efficacy of the renin inhibitor aliskiren

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...